Hematologic Malignancy
High Grade B-Cell Lymphoma
CI-CAN-00007803HGBLExplore in graph →
Hematologic84 active trials2 approved drugs
- NCIt
- C138211
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00007803HGBLExplore in graph →
Clinical trials
142 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (16)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05075603 | Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy | completed | Phase 1 | 17 | NeoImmuneTechINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05653271 | ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies | completed | Phase 1 | 16 | Acepodia Biotech, Inc.INDUSTRY | 3 | Jun 30, 2026 | clinicaltrials |
| NCT04067414 |
| Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma |
| completed |
| Phase 1 |
| 12 |
| Institute of Hematology & Blood Diseases Hospital, ChinaOTHER |
| 1 |
| Feb 11, 2026 |
| clinicaltrials |
| NCT03742258 | Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma | completed | Phase 1 | 12 | Northwestern UniversityOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT04555811 | FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL | completed | Phase 1 | 7 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT02348216 | Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma(ZUMA-1) | completed | Phase 1 / Phase 2 | 307 | Kite, A Gilead CompanyINDUSTRY | 6 | Jun 4, 2024 | clinicaltrials |
| NCT03309878 | Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma | completed | Phase 1 / Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03036904 | Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas(V+DA-EPOCH-R) | completed | Phase 1 | 31 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT01742988 | Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma | completed | Phase 1 | 106 | Curis, Inc.INDUSTRY | 1 | May 6, 2021 | clinicaltrials |
| NCT01897012 | Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | completed | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Jan 28, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Aug 10, 2026source: clinicaltrials